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Abstract
Background: There is substantial evidence to support the association between tuberculosis (TB) and tobacco
smoking and that the smoking-related immunological abnormalities in TB are reversible within six weeks of
cessation. Therefore, connecting TB and tobacco cessation interventions may produce significant benefits and
positively impact TB treatment outcomes. However, no study has extensively documented the evidence of benefits
of such integration. SCIDOTS Project is a study from the context of a developing nation aimed to determine this.
Methods: An integrated TB-tobacco intervention was provided by trained TB directly observed therapy short-
course (DOTS) providers at five chest clinics in Malaysia. The study was a prospective non-randomized controlled
intervention using quasi-experimental design. Using Transtheoretical Model approach, 120 eligible participants who
were current smokers at the time of TB diagnosis were assigned to either of two treatment groups: conventional
TB DOTS plus smoking cessation intervention (integrated intervention or SCIDOTS group) or conventional TB DOTS
alone (comparison or DOTS group). At baseline, newly diagnosed TB patients considering quitting smoking within
the next 30 days were placed in the integrated intervention group, while those who were contemplating quitting
were assigned to the comparison group. Eleven sessions of individualized cognitive behavioral therapy with or
without nicotine replacement therapy were provided to each participant in the integrated intervention group. The
impacts of the novel approach on biochemically validated smoking cessation and TB treatment outcomes were
measured periodically as appropriate.
Results: A linear effect on both 7-day point prevalence abstinence and continuous abstinence was observed over
time in the intervention group. At the end of 6 months, patients who received the integrated intervention had
significantly higher rate of success in quitting smoking when compared with those who received the conventional
TB treatment alone (77.5% vs. 8.7%; p < 0.001). Furthermore, at the end of TB treatment (6 months or later), there
were significantly higher rates of treatment default (15.2% vs. 2.5%; p = 0.019) and treatment failure (6.5% vs. 0%; p
= 0.019) in the DOTS group than in the SCIDOTS group.
Conclusion: This study provides evidence that connecting TB-tobacco treatment strategy is significant among TB
patients who are smokers. The findings suggest that the integrated approach may be beneficial and confer
advantages on short-term outcomes and possibly on future lung health of TB patients who quit smoking. This
study may have important implications on health policy and clinical practice related to TB management among
tobacco users.
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Tuberculosis (TB) and tobacco smoking are currently
two formidable public health concerns and indepen-
dently pose a considerable threat to global health [1-3].
The current estimates put the annual global mortality
from the two epidemics at over six million [2,3]. It is
remarkable to note that TB and tobacco use are co-pre-
valent in many developing nations and these nations are
said to be doubly burdened by the collision of the two
epidemics [1,4]. In addition, there is substantial and
overwhelming evidence to conclude that smoking is
strongly linked to TB disease and leads to poor treat-
ment outcomes [5-11]. It is consistently reported also
that the prevalence of smoking among TB patients was
high when compared with non-TB controls or the gen-
eral population [12-17]. Consequently, this subject has
in recent years attracted and received a widespread
attention among the scientific community around the
world.
Although there is paucity of data on the direct effects
of smoking cessation on TB treatment outcomes [18],
studies suggest that smokers are at an increased risk of
treatment default, treatment failure, and relapse after
successful treatment [8-11,19]. It is also well documen-
ted that tobacco smoking suppresses both cell- and
humoral-mediated immunity thereby causing TB infec-
tion and worsening the outcomes of treatment [20].
However, most of the immunological abnormalities
induced by smoking including decreased level of circu-
lating immunoglobulins, decreased ratio of CD4
+ to
CD8
+ lymphoctyes, and decreased release of proinflam-
matory cytokines are reversible within six weeks after
smoking cessation [20-23]. Thus, it is strongly recom-
mended that smoking cessation using both cognitive
behavioral therapy and pharmacotherapeutic approach
be incorporated as a standard of care in directly
observed therapy short-course (DOTS) and other TB
treatment strategies [14,18].
Furthermore, a few guidelines and educational series
addressing the control of tobacco use in TB settings
have recently been developed [24-32]. Despite the over-
whelming evidence of association between TB and
tobacco use, the recent availability of guidelines on how
to integrate the management of these related epidemics,
and the anticipated benefits of quitting smoking, there
are several unanswered questions which warrant further
research [4,14]. Connecting the two healthcare interven-
tions could produce significant benefits and is appar-
ently logical [4,14]. What are the potential benefits of
the integrated approach in improving the outcomes of
TB among smokers? In order to address this query,
research efforts are needed to determine both the short-
term and long-term benefits of smoking cessation in
TB care.
The results of such studies could guide the develop-
ment of evidence-informed practice guidelines, devoid
of mere speculations and assumptions. In an effort to
establish an evidence and policy direction and to expand
the current knowledge of the impact of integrated TB-
tobacco treatment strategy in improving treatment out-
comes, quality of life, and reducing healthcare resources
utilization, we set out to conduct intervention studies
related to above in Malaysia. The present study, known
as the SCIDOTS Project, was primarily aimed to evalu-
ate the impact of adding smoking cessation intervention
(SCI) to conventional DOTS for TB on tobacco absti-
nence rates and TB treatment outcomes.
Methods
Study Design
We conducted a prospective non-randomized controlled
intervention study using quasi-experimental design. New
cases of TB who currently smoke cigarettes at the time
of diagnosis were assigned to either of two intervention
groups, based upon their readiness to quit smoking
measured through Transtheoretical Model approach
[33]: conventional TB DOTS alone (comparison or
DOTS group) or the conventional TB DOTS plus SCI
(integrated intervention or SCIDOTS group).
The non-equivalent comparison group design was used
instead of a randomized controlled trial (RCT) design to
overcome practical issues and ethical imperatives asso-
ciated with the RCT among TB patients who smoke.
Study Setting and Ethical Approval
A multi-centered study was conducted at five respiratory
clinics: four located within Penang State health districts
and one in Wilayah Persekutuan Kuala Lumpur, Malay-
sia. The selected clinics were considered as TB referral
centers from which all diagnosis or confirmation of TB
cases must come from among the population they serve.
Initiation of treatment for confirmed TB cases must also
stem from such centers. The study was carried-out dur-
ing the period June 2008 to December 2009. The study
was approved by the Medical Research Ethics Commit-
tee of the National Institutes of Health, Ministry of
Health, Malaysia.
Study Sample and Participants
The sample of the study comprised of all current manu-
factured cigarette smokers newly diagnosed with active
TB. Patients were identified based on their self-reported
tobacco use during TB diagnosis. They were then
referred at the point of initiating DOTS regimen by the
attending physician to TB DOTS providers who were
specially trained to provide SCI in TB setting [34].
Patients were recruited into the study upon fulfillment
of eligibility criteria and written informed consent.
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ments were based is the comparison of the proportion
of patients cured of TB (cure rates) and treatment fail-
ure rates between the two treatment groups. For the
primary outcome comparison between the integrated
intervention (SCIDOTS) group and the comparison
(DOTS) group, a statistical power (1- b)o f8 0 %t o
detect a moderate effect size at a 95% confidence level
was set. Since DOTS has a target to achieve a 95% cure
rate in previous reports, we assumed a cure of 95% in
the intervention arm (p1 = 0.95) and 75% in the control
arm (p2 = 0.75). A minimum sample size of 48 subjects
was estimated per treatment arm for the study to have a
statistical power of 80% to detect a difference of 20% in
TB cure rates with a 2-sided alpha level of 0.05. Assum-
ing a dropout rate of 25%, about 60 participants would
be required for each treatment arm. Therefore, a total
of 120 subjects (60 for each treatment group) was tar-
geted in the study.
Enrollment Procedures and Eligibility Criteria
The 5A’s strategy (Ask, Advise, Assess, Assist, Arrange)
and the Transtheoretical Model of Stages of Change
were used in the assignment of patients into the two
treatment groups of the study [33,35]. First, all newly
diagnosed TB patients were “asked” about their smoking
status. Patients who declared their smoking status as
current smokers were strongly and clearly “advised” to
quit smoking, given the benefits of cessation and linking
it with their current disease status. Patient’s willingness
to quit smoking was “assessed” using the 5-stage Trans-
theoretical Model (precontemplation, contemplation,
preparation, action, and maintenance) and motivation
assessment. Only patients in the preparation stage
(defined as willingness to quit smoking within the next
30 days), or contemplation stage (considering quitting in
the next 6 months, but not in the next 30 days), or pre-
contemplation stage (not thinking about changing in the
next 6 months) were invited to participate in the study
by individual letters served during initiation of DOTS.
Sixty patients motivated to quit smoking (in preparation
stage) who gave their consent were enrolled into the
integrated intervention group (to receive SCI in addition
to DOTS), whereas another 60 unmotivated patients (in
precontemplation and contemplation stages) willing to
participate in the research were recruited into the usual
care group (to receive conventional DOTS regimen).
Patients were invited to participate in the study if they
fulfilled the following criteria: (1) current manufactured
cigarette smokers diagnosed with active pulmonary TB:
either sputum smear-positive or smear-negative, based
on classification from Malaysian or WHO treatment
guidelines, [36,37], (2) classified under treatment Cate-
gory I (new TB cases), (3) patients of both sexes, aged
18 years and above, and (4) patients in preparation, pre-
contemplation, or contemplation stages of behavior
change. Furthermore, newly diagnosed TB patients were
excluded from the study if: (1) they were in action and
maintenance stages of behavior change, (2) have extra-
pulmonary TB only (involving CNS, pericardium, adre-
nal etc), (3) they have multi-drug resistant tuberculosis
at diagnosis, (4) they are living with or newly diagnosed
with HIV/AIDS, (5) they are classified as Category II
(relapse, treatment failure, and treatment after default)
or Category III (chronic TB), and (6) they fulfilled the
eligibility criteria, but unwilling to participate in
the study or unable to understand the contents of the
informed consent form.
Figure 1 schematically illustrates the allocation of
study participants into groups and the methods used in
the study.
Interventions and Monitoring
At the first visit, patients in the intervention group
received an overview of the integrated DOTS plus SCI
program, whereas the usual care group received an over-
view of DOTS plus conventional TB counseling. Ques-
tionnaires to assess tobacco use and smoking history
were completed and all patients took the Fagerström
test for nicotine dependence (FTND) at baseline. During
this visit, patients in the intervention group were asked
to establish a target quit date (within one month from
the first visit).
Patient-centered intervention techniques were
employed for all recruited patients, using the 5A’ss t r a t -
egy. At the initial visit (i.e. on the quit date) and each
subsequent visit, patients in the intervention group
received personalized behavioral counseling, educational
materials, and refills of drug prescriptions related to
smoking cessation; in addition to DOTS for TB. The
behavioral counseling was individualized to work with
patients in modifying behaviors and achieving success.
Drug therapy for tobacco cessation comprised of four
types of nicotine replacement therapy (NRT) products
(nicotine gum 2 mg and 4 mg, nicotine transdermal
patch, and nicotine inhaler).
Patients in both treatment groups went to the chest
clinic on daily-basis to receive DOTS. Follow-up sche-
dules for TB were on 2-monthly basis (baseline, end of
second, fourth, and sixth month). The follow-up clinic
appointments for SCI (beginning on the quit date) were
as follows: weekly for the first month, fortnightly for the
second and third month, and monthly from the fourth
to the sixth month; giving rise to a total of 11 follow-up
visits. NRT and behavioral counseling were modified
throughout the follow-up period after evaluation of the
patient’s progress. Validation of cessation was performed
via breath carbon monoxide (CO) monitoring using
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Page 3 of 13Micro™-Smokerlyzer™, one-way valve single-use
mouthpieces, suitable for infection patients (Bedfont
Scientific Ltd & decode, UK) and saliva cotinine dip-
stick test (NikAlert
®). Patient-reported nicotine withdra-
wal symptoms were measured using Wisconsin Smoking
Withdrawal Scale (WSWS), validated in Malay language.
Participants were monitored during each follow-up
visit for nicotine dependence, exhaled CO level, and
nicotine withdrawal symptoms. Further, saliva cotinine
testing was conducted during the last follow-up visit as
a biochemical measure of verifying quitting. Both
CO and cotinine are widely used as biomarkers for
 
TT = transtheoretical; 
aSmoking cessation outcomes were measured 11 times based on 
the number of follow-ups recommended in the guidelines.  
TB Patients Category 1 (who smoke & fulfilled eligibility criteria) 
Precontemplation  Contemplation  Prep  Action  Maintenance 
≤ 6 months  30 days 
Quit 
Date 
≥ 6 months 
Population 
TT Model 
(Stages of 
Change) 
Volunteered to participate  Volunteered to participate  Consent 
Conventional Care Group (n = 60)  Integrate Intervention Group (n = 60)  Recruitment  
 
DOTS Only 
[6 months anti-TB regime] 
 
DOTS + SCI (value-added service) 
[6 months anti-TB regime] 
+ 
[6 months CBT ± NRT] 
SCI Outcomes 
Â  7-day Point Prevalence Abstinence 
(3 and 6 months) 
Â  Continuous Prevalence Abstinence 
(3 and 6 months) 
 
TB Treatment Outcomes 
Â Clinical (2, 4, and 6 months) 
Â HRQoL (3 and 6 months) 
SCI Outcomes
a 
Â  7-day Point Prevalence Abstinence 
(3 and 6 months) 
Â  Continuous Prevalence Abstinence 
(3 and 6 months) 
 
TB Treatment Outcomes 
Â Clinical (2, 4, and 6 months) 
Â HRQoL (3 and 6 months) 
Intervention  
Follow-up / 
Outcomes 
measurement 
Figure 1 Flowchart of subjects’ enrollment/allocation and study methodology.
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Page 4 of 13confirming smoking abstinence. For each participant in
the intervention group, these measurements were con-
ducted 12 times including baseline. Each subject was
followed for a period of at least 6 months to determine
the outcomes of TB and tobacco dependence treatment.
Statistical Analysis
All data were double-entered into SPSS version 16.0
software package (SPSS Inc., Chicago, IL) by one
researcher and two research assistants using two sepa-
rate databases that were later compared and differences
reconciled by re-checking the raw data. Patients’ demo-
graphic information, baseline TB- and tobacco-related
characteristics were calculated as mean ± SD for contin-
uous variables and as proportions for categorical vari-
ables. To explore the comparability of demographic, TB-
and smoking-related characteristics between the two
treatment groups, homogeneity of the baseline data was
measured using two-sample tests including Student’s t-
test for normally distributed continuous variables, and
Pearson’sc h i - s q u a r e( c
2)o rF i s h e r ’s exact test for cate-
gorical variables. TB treatment outcomes were com-
pared between the integrated intervention and the
comparison groups using Pearson’s c
2 or Fisher’se x a c t
test and Mann Whitney-U test at 2 months, 4 months,
and 6 months or end of treatment. These nonparametric
statistical tests were also applied to compare smoking
abstinence rates (continuous abstinence and point pre-
valence abstinence) between the two treatment arms at
3 months and 6 months.
Results
Of the 120 eligible patients recruited into the study, 86
patients (71.7%) completed the intervention and follow-
up; 40 participants (46.5%) received the SCIDOTS,
whereas 46 participants (53.5%) received the conven-
tional DOTS alone. All the 86 patients were included in
the data analysis. Thirty-four of the enrolled participants
were lost to follow-up, giving rise to an overall attrition
rate of 28.3%. During the intervention and follow-up
period, 20 (33.3%) and 14 (23.3%) participants in the
integrated intervention and the comparison arms
respectively were lost to follow-up. In the intervention
group, 10 patients withdrew their consent, three were
diagnosed as HIV-positive, six were either transferred to
other treatment centers or unable to contact, and one
was incarcerated. In addition, nine patients in the com-
parison group withdrew their consent, one turned out
to be HIV-positive, whereas four were either transferred
to other treatment centers or not contactable. Conse-
quently, data were collected from 40 patients and 46
patients in the SCIDOTS and the DOTS groups respec-
tively throughout the study period of six months or
longer.
Group Equivalence for Demographic, Smoking and
Disease-Related Characteristics
We compared the study groups in order to ascertain
whether they were similar in related characteristics,
despite lack of randomization. Subjects in the two
groups were homogenous with respect to most of the
characteristics. Table 1 presents the comparison of the
demographic characteristics of the study participants.
The groups did not differ significantly with regards to
the distribution of age (t =-1.33, p = 0.186), gender
(Fisher’s exact p = 1.000), ethnicity (Fisher’s exact p =
0.431), and marital status (Fisher’s exact p = 0.961).
In addition, most of the baseline smoking habits and
smoking-related characteristics of the enrolled TB smo-
kers were not significantly different between the two
treatment groups (Table 2). In both groups, TB patients
smoked about 16 cigarettes per day on the average.
Patients in the DOTS group had smoked for 28.63 ±
13.25 years in their lifetime vs. 24.80 ± 13.49 years for
those in the SCIDOTS group (t = -1.326, p = 0.188).
However, the distribution of nicotine dependence signif-
icantly differed between the two groups and subjects in
the DOTS group were more dependent on nicotine than
those in the SCIDOTS group (FTND, 5.43 ± 1.96 vs.
4.32 ± 2.26; t = -2.439, p = 0.017). Moreover, the mean
CO level of the DOTS group was higher when com-
pared with the SCIDOTS group (7.61 ± 3.61 ppm vs.
5.93 ± 2.83 ppm; t = -2.370, p = 0.020). The clinical pre-
sentations of TB were equally distributed between the
treatment groups during diagnosis. Nearly all patients
(97.8-100%) in both groups presented with cough of
more than two weeks duration, but hemoptysis and dys-
pnea were relatively less common. Similarly, tuberculin
skin test (TST) and chest X-ray findings were similar
among the DOTS and the SCIDOTS groups.
Smoking Cessation Interventions and Outcomes
Monitoring
All participants enrolled in the intervention group were
provided with either CBT alone (40%) or combination
of CBT and NRT products (60%). Of those who received
concomitant therapy, about one-third were on nicotine
gum 2 mg. Only 8.3% of the integrated intervention
cohort had received therapy with nicotine gum 4 mg
and nicotine inhaler each. Table 3 provides additional
details on the types of SCI provided and the NRT pro-
ducts used.
Both expired CO level and FTND were consistently
and significantly lower in the SCIDOTS group when
compared with the DOTS group for all time periods
(Table 4). When tested for cotinine using saliva as a bio-
logical matrix at the end of the treatment, 77.5% vs.
17.4% of patients in the SCIDOTS and the DOTS
groups respectively had concentration of 0-10 ng/mL
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these.
Effect of the Intervention on Smoking Cessation
Outcomes
A linear effect on biochemically-confirmed 7-day point
prevalence abstinence (PPA) and continuous abstinence
(CA) was observed over time in the intervention group;
both the 7-day PPA and the CA rates were 45.0% (18/
40) at one month after the quit date, but increased to
62.5% (25/40) and 60.0% (24/40) respectively at 2
months. This trend increased linearly over time until
the success rate plateau at the end of fifth month and
slightly decreased at the end of sixth month. The
linearity of quitting rates in relation to time is illustrated
in Figure 2.
Furthermore, at 3 months after the quit date, patients
who received the integrated intervention had a signifi-
cantly higher rate of success in quitting smoking when
compared with those who received the usual TB care
alone (70.0% vs. 10.9%, respectively; (Pearson c
2 =
31.63, df = 1, N = 86; p < 0.001) (Table 5). In addition,
at the end of the 6-month follow-up, the one-month
self-reported CA rate, confirmed biochemically by both
CO and saliva cotinine tests, was nearly 78% (31/40) in
the intervention group versus 9% (4/46) in the usual
care group (Pearson c
2 = 41.97, df = 1, N = 86; p <
0.001).
Table 1 Demographic characteristics of the study participants (N = 86)
Characteristic Comparison Group (DOTS only)
(n = 46)
Intervention Group (DOTS + SCI)
(n = 40)
p-value
a
Mean age at time of enrolment (years) 45.78 ± 14.42 41.62 ± 14.41 0.186
b
Mean body weight (kg) 50.33 ± 8.82 53.30 ± 10.67 0.162
b
Male gender, no. (%) 45 (97.8%) 40 (100.0%) 1.000
Ethnicity, no. (%) 0.431
￿ Malay 29 (63.0%) 30 (75.0%)
￿ Chinese 11 (23.9%) 8 (20.0%)
￿ Indian 5 (10.9%) 1 (2.5%)
￿ Other 1 (2.2%) 1 (2.5%)
Marital status, no. (%) 0.961
￿ Single 17 (37.0%) 14 (35.0%)
￿ Married 24 (52.2%) 22 (55.0%)
￿ Divorced 2 (4.3%) 1 (2.5%)
￿ Other 3 (6.5%) 3 (7.5%)
aFisher’s exact test and
bIndependent t-test were applied in calculating p-values.
DOTS = directly observed therapy short-course; SCI = smoking cessation intervention
Table 2 Smoking history and baseline smoking-related characteristics of the study participants (N = 86)
Characteristic Comparison Group (DOTS only)
(n = 46)
Intervention Group (DOTS + SCI)
(n = 40)
p-value
a
Smoking habits/history
￿ Mean age when began
smoking (years)
17.37 ± 3.55 16.88 ± 4.31 0.561
￿ Mean duration of smoking
(years)
28.63 ± 13.25 24.80 ± 13.49 0.188
￿ Mean cigarettes per day 16.70 ± 9.62 16.02 ± 8.54 0.735
Mean FTND score 5.43 ± 1.96 4.32 ± 2.26 0.017
Nicotine dependence at enrolment, no. (%) 0.048
b
￿ High (7-10) 15 (32.6%) 8 (20.0%)
￿ Moderate (4-6) 25 (54.3%) 18 (45.0%)
￿ Minimal (less than 4) 6 (13.0%) 14 (35.0%)
Previous attempt to quit, no. (%) 18 (39.1%) 21 (52.5%) 0.214
b
Mean breath CO (ppm) 7.61 ± 3.61 5.93 ± 2.83 0.020
Mean WSWS score 53.09 ± 10.69 56.00 ± 12.42 0.246
aIndependent t-test was applied in calculating p-values;
bChi-square (c
2) test.
DOTS = directly observed therapy short-course; FTND = Fagerström test for nicotine dependence; SCI = smoking cessation intervention; WSWS = Wisconsin
smoking withdrawal scale
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There were no significant differences between the two
treatment groups in the distribution of anti-TB drugs
regimen, duration of treatment, and drugs doses during
both the intensive and the maintenance phases of treat-
ment. Nearly all patients in both groups received the
EHRZ regimen consisting of ethambutol, isoniazid,
rifampicin, and pyrazinamide once daily dosing during
the 2-month intensive phase, whereas more than 70%
were on H2R2 regimen comprising of isoniazid and
rifampicin twice weekly dosing during the 4-month
maintenance phase. The median duration of the inten-
sive phase was 2 months in both groups.
Sputum direct smear positivity for acid fast bacilli
(AFB) was significantly higher among the participants in
the integrated intervention group than among those in
the usual care group at baseline (i.e. during diagnosis);
92.5% vs. 73.9% (Pearson c
2 =5 . 1 3 ,d f=1 ,N=8 6 ;p=
0.023). However, the proportion of patients with positive
sputum smear in both groups drastically decreased at
the end of two months and four months of TB treat-
ment, with no significant differences between the treat-
ment groups (Table 6). Conversely, at the end of six
months of DOTS regimen, the SCIDOTS group had sig-
nificantly higher sputum smear conversion (negative
smear test result) than did the DOTS group (100.0% vs.
93.9%; Fisher’s exact p = 0.043).
The baseline radiological presentations of the patients
were not significantly different between treatment arms.
Nevertheless, as the treatment progressed over time,
Table 3 Smoking cessation intervention for the
integrated intervention group (n = 40)
Intervention No. (%)
Type of smoking cessation intervention
CBT only 16 (40.0%)
CBT + NRT 24 (60.0%)
Pharmacotherapeutic agent (NRT product type)
Nicotine gum 2 mg 8 (33.3%)
Nicotine gum 4 mg 2 (8.3%)
Nicotine patch (5 mg/10 mg/15 mg) 2 (8.3%)
Nicotine inhaler 10 mg 3 (12.5%)
Nicotine gum 4 mg/Nicotine gum 2mg 3 (12.5%)
Nicotine gum 2 mg/Nicotine patch 1 (4.2%)
Other combinations 5 (20.8%)
Frequency of CBT encounters
9 1 (2.5%)
10 2 (5.0%)
11 36 (90.0%)
12 1 (2.5%)
CBT = Cognitive behavioral therapy; NRT = Nicotine replacement therapy
Table 4 Smoking cessation monitoring according to group assignment*
Monitoring parameter DOTS
(n = 46)
SCIDOTS
(n = 40)
p-value
†
Baseline (Week 0)
Breath CO (ppm) 7.61 ± 3.61 5.93 ± 2.83 0.020
FTND 5.43 ± 1.96 4.32 ± 2.26 0.017
WSWS 53.09 ± 10.69 56.00 ± 12.42 0.246
End of 3
rd month post quit date (Week 12)
Breath CO (ppm) 7.30 ± 2.99 1.98 ± 1.25 < 0.001
FTND 4.87 ± 2.10 0.15 ± 0.53 < 0.001
WSWS 51.39 ± 9.81 47.95 ± 10.70 0.123
End of 6
th month post quit date (Week 24)
Breath CO (ppm) 8.00 ± 3.58 1.83 ± 2.47 < 0.001
FTND 4.57 ± 1.70 0.25 ± 0.71 < 0.001
WSWS 51.87 ± 9.43 48.20 ± 9.14 0.072
Negative cotinine test (0-10 ng/mL), n (%) 8 (17.4%) 31 (77.5%) < 0.001
‡
* Plus-minus values are means ± SD;
†p-values were calculated with the use of independent t-test for all continuous data reporting mean values;
‡p-value was
calculated using Chi-square (c
2) test.
FTND = Fagerström test for nicotine dependence; WSWS = Wisconsin smoking withdrawal scale
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Figure 2 Linearity of smoking cessation outcome for the
intervention group: Continuous abstinence (CA).
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ray findings, with subjects in the integrated intervention
group showing better response to treatment (Table 7). At
six months, the response rate was better among the inte-
grated intervention patients than the standard care patients;
proportions of patients with no lesion were 67.5% vs.
34.8%, respectively (Mann Whitney-U = 588.00; p = 0.001).
Effect of the Intervention on TB Treatment Outcomes
Treatment default rate during two months and four
months of TB treatment was higher among the
conventional DOTS group when compared with the
SCIDOTS group, although the difference at two months
failed to reach statistical significance (Table 8). At the
end of six months, however, the default rate was signifi-
cantly lower among the integrated intervention (SCI-
DOTS) group when compared with the usual care
(DOTS) group (2.5% vs. 15.2%; Fisher’s exact p = 0.031).
In addition, the cure rate was significantly higher among
the former than the latter group (62.5% vs. 34.8%; Fish-
er’s exact p = 0.031).
Because TB treatment was extended beyond six
months for many patients, we followed them in order to
re-assess the overall TB treatment outcomes. The
DOTS group when compared with the SCIDOTS group
still maintained higher treatment default (15.2% vs.
2.5%) and failure rates (6.5% vs. 0%) (Table 8). Overall,
the cure plus treatment completion rate (success rate)
was 97.5% in the integrated intervention group, as com-
pared with 78.3% in the comparison group (Fisher’s
exact p = 0.019).
Discussion
T h ep r e s e n ts t u d yh a si n v e s t i g a t e dt h eo u t c o m e so fa n
integrated tobacco cessation intervention in TB care
and its impact on TB treatment outcomes. When care-
fully interpreted, the results of the SCIDOTS Project
may provide an evidence of the short-term benefits of
connecting tobacco cessation intervention with TB
DOTS. The study employed non-equivalent compari-
son group design for a question that may be better
approached using a RCT design due to some major
considerations. First, the provision of treatment for
tobacco use and dependence in clinical settings is
solely based on patient’s readiness to quit smoking or
stage of change, owing to the addictive nature of the
disease and facts documented by the existing treatment
Table 5 Smoking cessation outcomes according to group assignment
Outcome measure DOTS
(n = 46)
SCIDOTS
(n = 40)
p-value
a
Abstinence rate, no. (%)
On quit date (Week 0)
b
7-day point prevalence abstinence 0 (0%) 0 (0%) -
Continuous abstinence (2 weeks) 0 (0%) 0 (0%) -
End of 3
rd month post quit date (Week 12)
b
7-day point prevalence abstinence 6 (13.0%) 30 (75.0%) < 0.001
Continuous abstinence (2 weeks) 5 (10.9%) 28 (70.0%) < 0.001
End of 6
th month post quit date (Week 24)
c
7-day point prevalence abstinence 5 (10.9%) 33 (82.5%) < 0.001
Continuous abstinence (4 weeks) 4 (8.7%) 31 (77.5%) < 0.001
aChi-square (c
2) test was used in calculating p-values.
bPatient-reported abstinence verified biochemically using breath CO analysis.
cPatient-reported abstinence verified biochemically using breath CO analysis and saliva cotinine testing.
Table 6 Group comparison of treatment response:
sputum direct smear
Sputum AFB direct smear, no. (%) Positive Negative
Baseline Comparison Group
(n = 46)
34 (73.9%) 12 (26.1%)
Intervention Group
(n = 40)
37 (92.5%) 3 (7.5%)
p-value 0.023
a
2 months Comparison Group
(n = 37)
7 (18.9%) 30 (81.1%)
Intervention Group
(n = 32)
6 (18.8%) 26 (81.2%)
p-value 0.999
a
4 months Comparison Group
(n = 33)
2 (6.1%) 31 (93.9%)
Intervention Group
(n = 31)
1 (3.2%) 30 (96.8%)
p-value 0.713
b
6 months Comparison Group
(n = 33)
2 (6.1%) 31 (93.9%)
Intervention Group
(n = 35)
0 (0%) 35 (100.0%)
p-value 0.043
b
aChi-square (c
2) test and
bFisher’s exact test were applied in calculating p-values.
AFB = acid fast bacilli
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may potentially fail if provided to a patient in the con-
templation stage of change. Therefore, in order to run
a RCT successfully, it is imperative to use effective and
practical research strategies [40]. Second, the provision
of tobacco cessation intervention is a medical impera-
tive [41]; therefore, there is ethical dilemma in rando-
mizing patients to no treatment (control group) when
they are in the “preparation stage” of behavior change
and given the potential positive impacts of quitting
Table 7 Group comparison of treatment response: radiological findings
Chest X-ray changes, no. (%) No lesion Minimal Moderately advanced Far advanced
Baseline Comparison Group
(n = 46)
1 (2.2%) 16 (34.8%) 23 (50.0%) 6 (13.0%)
Intervention Group
(n = 40)
0 (0%) 21 (52.5%) 15 (37.5%) 4 (10.0%)
p-value/MW-U 0.212/788.5
2 months Comparison Group
(n = 45)
1 (2.2%) 22 (48.9%) 19 (42.2%) 3 (6.7%)
Intervention Group
(n = 40)
7 (17.5%) 25 (62.5%) 7 (17.5%) 1 (2.5%)
p-value/MW-U 0.003/614.5
4 months Comparison Group
(n = 46)
6 (13.0%) 21 (45.7%) 18 (39.1%) 1 (2.2%)
Intervention Group
(n = 38)
13 (34.2%) 22 (57.9%) 3 (7.9%) 0 (0.0%)
p-value/MW-U < 0.001/510.0
6 months Comparison Group
(n = 46)
16 (34.8%) 16 (34.8%) 14 (30.4%) 0 (0.0%)
Intervention Group
(n = 40)
27 (67.5%) 11 (27.5%) 2 (5.0%) 0 (0.0%)
p-value/MW-U 0.001/588.0
Mann Whitney-Utest was applied in calculating p-values. MW-U = Mann Whitney-U
Table 8 TB treatment outcomes during follow-up according to group assignment
Outcome Comparison Group,
DOTS only
(n = 46)
Intervention Group, DOTS + SCI
(n = 40)
p-value
a
no. (%)
End of 2 months
Treatment interrupted 4 (8.7%) 0 (0%) 0.120
Treatment in progress 42 (91.3%) 40 (100.0%)
End of 4 months
Treatment interrupted 7 (15.2%) 1 (2.5) 0.045
Treatment in progress 39 (84.8%) 39 (97.5%)
End of 6 months
Cured 16 (34.8%) 25 (62.5%) 0.031
Treatment completed 6 (13.0%) 3 (7.5%)
Treatment interrupted 7 (15.2%) 1 (2.5%)
Treatment failed 3 (6.5%) 0 (0%)
Treatment in progress 14 (30.4%) 11 (27.5%)
Overall treatment outcome
Cured 24 (52.2%) 32 (80.0%) 0.019
Treatment completed 12 (26.1%) 7 (17.5%)
Treatment interrupted 7 (15.2%) 1 (2.5%)
Treatment failure 3 (6.5%) 0 (0%)
aFisher’s exact test was applied in calculating p-values.
DOTS = directly observed therapy short-course; SCI = smoking cessation intervention
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Page 9 of 13smoking on TB treatment outcomes and future lung
health.
At the end of six months post-quit date, the current
study has documented a tremendous abstinence rate of
78% among the patients undergoing tobacco cessation
intervention versus only 9% among the patients who did
not receive the value-added intervention. It is interesting
to note that the increase over time in biochemically-
confirmed patient-reported abstinence was linear. The
smoking cessation rate recorded at the end of six month
post-quit date in this study was much higher than that
reported in the general population, which centers
around 10 to 33% [35,38,42]. This is probably because
patients who are ill are more likely to be receptive to
health messages and comply with the advice given by
the healthcare provider [29]. Therefore, treating tobacco
dependence during TB treatment is a teachable moment
that has an important implication on success to quitting
[4,29]. However, the study compared persons motivated
to quit smoking in an intervention group to those con-
templating quitting smoking in a comparison group;
therefore, the observed difference in smoking cessation
between the groups would likely not have been so great.
Unfortunately, data with which a direct comparison of
the current findings can be made are scanty since much
of the previous studies were surveys based on previous
TB patients self-reports or some form of observational
studies. In a pioneering work performed by El Sony and
colleagues in Sudan, the investigators reported a 66%
(165/252) abstinence rate at the end of TB treatment
among those who were enrolled in a tobacco cessation
program vs. 14.3% (6/42) in the control group [43]. One
important limitation of the former study was lack of
biochemical validation of abstinence. The study also did
not statistically compare changes over time in smoking
abstinence between the intervention and the control
groups. The intensity of the tobacco cessation interven-
tion used in the present study may account for the
higher quit rates observed in the integrated intervention
group when compared with other studies. Particularly,
participants enrolled in the integrated intervention
group had 11 follow-up visits for smoking cessation as
well as the use of both CBT and NRT for the treatment
of their tobacco dependence. Perhaps, these strategies
have lent some strength to the current study.
Furthermore, three recent observational studies from
Jogjakarta Province of Indonesia, the Indian state of
Kerala, and Yangzhong and Wujin County in China,
have highlighted smoking behaviors among former TB
patients [17,44,45]. In essence, 67-70% of former TB
patients admitted to receiving smoking cessation advice
or messages from healthcare providers at some point
during their treatment in TB settings [44,45]. A major
distinction between the former studies and the current
study is that the messages given were typically short
non-specific cessation messages mostly at the time of
diagnosis that were not necessarily followed up during
subsequent interactions with the physician or health
professional DOTS provider. It is recommended that
health professionals caring for TB patients should be
formally trained and encouraged to promote smoking
cessation, and to customize the interventions to those
suitable for TB patients (i.e. TB disease-specific mes-
sages and interventions) [25,28,29,34,45].
The majority (over 80%) of TB patients would quit
smoking during or soon after diagnosis, but at least
one-third of the sample surveyed relapsed during the six
months of treatment [44,45]. These findings though not
consistent with our study, revealed that the messages
received from healthcare providers in TB clinics could
play a significant role in aiding smoking cessation and
that more success might have been recorded if proactive
tobacco cessation interventions were provided. In con-
trast to our study in which the trend in smoking absti-
nence over time was positively linear in the integrated
intervention group, Ng et al. and Pradeepkumar et al.
studies have demonstrated a negative linear relationship
between quit rates and time.T h i si m p l i e st h a ts u c c e s s
in quitting smoking among the patients surveyed
declined over time during and after the course of TB
treatment. A probable explanation for such a distinct
contrast between the present study and others is that
the intensive nature of a tobacco cessation program
plays an important role in achieving and maintaining
quitting with lower chances of relapse. Previous studies
in the general population are also in support of this
hypothesis [46]. Most importantly, even the quit rates
documented by the two other group of researchers
might have likely been over-estimated, since quitting
was measured on the basis of self-reports from former
TB patients, subjecting the findings to high propensity
of recall bias and social desirability issues.
It was interesting that sputum smear conversion rate
was consistently higher among the SCIDOTS group
than the DOTS group, although this was not statistically
significant at the end of two months and four months.
This indicates a potential effect of tobacco cessation on
sputum smear conversion. A group of investigators
found that smokers and non-smokers converted with
similar frequency to a negative sputum status at the end
of two months (p = 0.065; OR, 0.47) [47]. However, they
noted that smokers with far advanced radiographic
abnormalities or with 3+ smear status, were found to
have a significantly lower chance of an early smear con-
version (p = 0.038 and p = 0.011, respectively). Similarly,
Leung et al. found that there was no statistically signifi-
cant difference in the smear conversion rate at two
months between smokers and non-smokers (OR 0.89, p
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failed to investigate further the influence of smoking on
sputum smear conversion beyond two months of TB
treatment. In the current study, we documented a signif-
icant difference in the sputum conversion rates between
participants in the integrated intervention and those in
the comparison groups at the end of sixth month; sug-
gesting that smoking may still delay sputum conversion
after two months of TB treatment. This observation
points to the needs for further investigations to eluci-
date the influence of continued smoking behavior
on smear conversion throughout the course of TB
treatment.
The delayed sputum smear conversion observed
among some subjects in the usual care group, who
apparently continued to smoke, might be explained by
the cascade of immunological activities associated with
tobacco smoking in causing infection and its persistence
[1,20,49]. Interestingly, most of the immunological
abnormalities associated with smoking are reversible
within six weeks of smoking cessation [20-23]. Probably
this supports the finding that an overwhelming propor-
tion of the participants who received the combined TB-
tobacco intervention had converted by four to six
months of treatment. In a nutshell, the current findings
suggest that sputum smear conversion is probably faster
among TB patients who quit smoking than those who
do not. This reaffirms the clinical implications of incor-
porating tobacco cessation as part of therapeutic plans
for patients newly diagnosed with TB disease.
Contrary to our findings, in the El Sony et al.’s study,
none of the differences between the TB treatment out-
comes of the intervention and control patients was sta-
tistically significant [43]. Perhaps this is the only study
that is comparable on head-to-head basis to the current
study. This is because, at present, it is the only pub-
lished study that involves prospective tobacco cessation
intervention among patients with TB. However, the
findings from that study should be carefully interpreted
in the light of the potential limitations associated with it
and somewhat variable study methodology and proce-
dures when compared with the current study. Although
the investigators separately followed both subjects at the
intervention and the control centers, yet substantial pro-
portions of the patients were non-smokers; 20% and
64% currently not using tobacco among participants in
the intervention and control centers, respectively. This
provides a hypothetical reason why the overall TB treat-
ment outcome, particularly cure/completion rate was
apparently better in the latter group than the former.
The authors emphasized that the primary goal of their
study was to examine the feasibility of including tobacco
cessation into TB services and not to test the hypothesis
that the combination would produce better treatment
outcomes. We also found that treatment failure was sig-
nificantly more common among participants in the
usual care group compared to the participants in the
integrated intervention group. This finding is not sur-
prising, with the evidence of reversibility of smoking-
related immunological abnormalities within six weeks
after cessation [20,22,23], emphasizing the potentials for
short-term benefits in recent quitters. Therefore, persis-
tent smokers are at greater likelihood of persistent infec-
tivity and poorer outcomes. Santha et al.f o u n dt h a tT B
patients under DOTS who currently smoked cigarettes
were at a significantly higher risk of treatment failure
than their counterparts who did not (OR 8.4, CI 1.0-
388; p = 0.04) [11].
Several non-interventional studies have equally demon-
strated the negative impact of tobacco smoking on TB
treatment outcomes [8-11,17,50]. It has been previously
documented that being a non-smoker is associated with a
greater chance of adherence to TB treatment (OR = 1.8;
95% confidence interval, CI = 1.0-3.3) [19]. However, it is
not well-known whether quitting smoking during TB
treatment would have immediate impact and produce
similar outcomes as those seen among never smokers.
Wang and Shen found that 11.3%, 15.0%, and 19.5% of
quitters, non-smokers, and persistent smokers were non-
adherent to DOTS regimen respectively [17]. Upon
adjustment for sociodemographic confounders, TB
patients without smoking cessation were twice more
likely to default treatment than those who achieved ces-
sation (OR 2.03; 95% CI 0.99-4.18) [17].
Similarly, in the present study, the rate of default at the
end of TB treatment was significantly higher among TB
patients in the usual care group when compared with the
patients in the integrated care group. This finding indi-
cates that tobacco cessation intervention could influence
patients’ adherence to treatment during the course of
DOTS. Of the seven patients who interrupted treatment
i nt h eu s u a lc a r eg r o u p ,m o r et h a n5 0 %d i ds ob yt h e
end of intensive phase of treatment. Therefore, SCI
should be initiated as soon as a patient is enrolled into a
DOTS program [51]. Evidence on the direct effects of
tobacco cessation on TB treatment outcomes is scanty,
yet recent observational studies indicate that TB patients
who continue to smoke during treatment remain at
greater risk to default treatment [17-19]. These observa-
tions corroborate the current findings, which are in the
context of an experimental environment.
In a Hong Kong study using a logistic risk model of
default (predictive power 85%), Chang and colleagues
found that the risk for defaulting treatment under DOTS
could be accurately predicted by smoking (OR 3.0, 95% CI
1.41-6.39, p = 0.004) among other factors [10]. This is also
supported by similar studies conducted in Tiruvallur Dis-
trict, South India and in Taiwan in which smoking among
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nificantly associated with a higher likelihood of treatment
default (OR 2.1, CI 1.3-3.4; p < 0.01 and OR 2.45, CI 1.22-
4.93; p < 0.05, respectively) [11,50]. From observations in
SCIDOTS Project, we conclude that regular patient-provi-
der interaction during DOTS reinforced by intensive
tobacco cessation follow-ups may significantly improve
adherence to TB regimens.
Overall, the present study underscores the potential
benefits of smoking cessation in improving outcomes
during the course of TB treatment. Therefore, the clini-
cal and practice implications of the current findings
include emphasis on the importance of connecting
smoking cessation as part of the therapeutic plans for
individuals newly diagnosed with TB.
T h e r ew e r ean u m b e ro fi n e v i t a b l el i m i t a t i o n si nt h e
present study. This study was a non-equivalent compari-
son group trial involving TB patients. The non-rando-
mized approach to group assignment was in the light of
the nature of nicotine addiction and ethical dilemma,
which necessitated us to adopt the Transtheoretical
Model of Stages of Change during the assignment of sub-
jects into the treatment groups. Therefore, there were
inherent potential threats to internal validity. One of
these is selection bias, because assignment to groups was
based on participant’s decision. There was also relatively
large dropout rate without intention-to-treat analysis. It
remains possible that TB patients who participated may
have differed in some important way from those who
were lost to follow-up. In addition, the study was limited
by its short follow-up periods; we did not follow subjects
after completion of DOTS to determine maintenance of
abstinence and long-term outcomes of TB. Furthermore,
the difference in nicotine dependence between the inter-
vention and the comparison groups might influence the
study results considering that the latter group had higher
nicotine dependence at baseline than the former. This
baseline difference can be controlled by considering the
baseline FTND score as a covariate in subsequent analy-
sis. In such circumstance, analysis of covariance
(ANCOVA) with repeated measures instead of analysis of
variance (ANOVA) is a statistical strategy to control for
such differences. Unfortunately, all the primary outcome
variables were non-parametric, which precludes the
application of this parametric test. Therefore, this was an
important limitation to this study. It is also worthwhile
to note that the success recorded in this study might be
influenced by Hawthorne effect as the intervention group
had follow-up visits more than the comparison group.
Conclusions
The potential salutary effects of connecting smoking
cessation to DOTS on improving TB therapeutic out-
comes were confirmed by the present study. The
findings suggest that the integrated approach may be
beneficial and confer advantages on short-term out-
comes and possibly on future lung health of TB patients
who quit smoking. Whether these effects are transient
or would be retained for a longer duration needs to be
further investigated. The results of this study might
have an important practice and policy implication in the
revision of TB treatment guidelines globally.
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